Skip to main content
. 2021 Sep 8;7(37):eabi4852. doi: 10.1126/sciadv.abi4852

Fig. 1. Tumor-associated anemia is accompanied by augmentation of extramedullary erythropoiesis.

Fig. 1.

Tumor was induced by injecting LLC cells into the flank of mice. (A) Time course of Hb levels in Ctrl and TB mice throughout the study. (B) Ter119+ erythroid cells were assessed in the bone marrow and spleen by flow cytometry. (C) CD71+ cells within the Ter119+ population were determined, and mRNA levels of gene involved in erythropoiesis and heme synthesis were measured in whole-spleen homogenate by semi quantitative polymerase chain reaction (qPCR). (D to F) Maturation of Ter119+ cells were analyzed according to their size and CD44 expression in the bone marrow (D), spleen (E), and blood (F) as shown in the representative flow cytometry plots and quantified in the bar graphs. (G) RBC size was assessed during the blood count using Advia 2021 (mean corpuscular volume). Groups (n = 6 per group) were compared by two-tailed unpaired t tests with Welch’s correction, and data are represented as means + SEM. Asterisks indicate differences between Ctrl and TB group. *P < 0.05, **P < 0.01, and ***P < 0.001. Kilt/SCF, kit ligand/stem cell factor; Tfrc/CD71, transferrin receptor; Gata1, GATA binding protein (erythroid transcription factor); Epor, EPO receptor; Alas2, 5′-aminolevulinate synthase 2 (erythroid-specific); Fech, ferrochelatase; FSC-A, forward scatter area.